Company: SXTPW
Filing Date: 2025-02-06
Form Type: 424B5
Source: 0001213900-25-010772
Chunk: 14

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-02-06
Form: 424B5
Chunk 14
---
8:, 1–13; Schlagenhauf et al Travel Medicine and Infectious           
 Disease 2022; 46:102268; See Arakoda prescribing information at www.arakoda.com; McCarthy et al CID 2019:69:480-486; Dow et al. Malar 
 J (2015) 14:473; Dow et al. Malaria Journal 2014, 13:49; Novitt-Moreno et al Travel Med Infect Dis 2022 Jan-Feb;45:102211.            |

| 25 | See prescribing information 
 at www.arakoda.com.         |

| 26 | See prescribing information 
 at www.arakoda.com.         |

| 27 | Dow and Smith, New Microbe       
 and New Infect 2022; 45: 100964. |

| 28 | Queener et al Journal of             
 Infectious Diseases 1992;165:764-8). |

| 29 | Liu et al. Antimicrobial                                                                                                         
 Agents Chemo 2021;65:e00204-21, Marcos et al. IDCases 2022;27:e01460; Rogers et al. Clin Infect Dis. 2022 Jun 10:ciac473, Prasad 
 and Wormsner. Pathogens 2022;11:1015.                                                                                            |

| 30 | Krause et al Clin Infect           
 Dis 2024; doi:10.1093/cid/ciae238. |

<div align='center'>S-5</div>

Celgosivir Celgosivir is a host targeted glucosidase inhibitor that was developed separately by other sponsors for HIV then for hepatitis C. 31The sponsors abandoned Celgosivir after completion of Phase II clinical trials involving 700+ patients, because other antivirals in development at the time had superior activity. The National University of Singapore initiated development of Celgosivir independently for Dengue fever. A clinical study, conducted in Singapore, the results of which were accepted for publication in the peer-reviewed journal Lancet Infectious Diseases, confirmed its safety but the observed reduction in viral load was lower than what the study was powered to detect. 32Celgosivir (as with other Dengue antivirals) exhibits greater capacity to cure Dengue infections in animal models when administered prior to symptom onset when compared to administration post-symptom onset. In animal models, this problem can be addressed by administering